BioAt­la heads for Nas­daq on Wednes­day fol­low­ing $189M IPO, go­ing pub­lic with its pH-de­tect­ing can­cer treat­ments

Yet an­oth­er biotech is mak­ing its pub­lic de­but Wednes­day, and this one comes just a few months af­ter a $72.5 mil­lion Se­ries D round.

BioAt­la be­comes 2020’s lat­est in­dus­try IPO, hav­ing raised an up­sized $189 mil­lion. Shares priced at $18 apiece, and with the biotech orig­i­nal­ly es­ti­mat­ing $136.4 mil­lion in its S-1, BioAt­la end­ed up rais­ing about 38.6% more than planned. The new­ly-pub­lic com­pa­ny will trade un­der the tick­er $BCAB once it of­fi­cial­ly hits the Nas­daq on Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER